Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>

ABSTRACT New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection with Mycobacterium tuberculosis. We report here on our work with AX-35, an arylvinylpiperazine amide, and four related analogs, which are potent antitubercular agents in vitro. All five compounds show...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caroline S. Foo, Andréanne Lupien, Maryline Kienle, Anthony Vocat, Andrej Benjak, Raphael Sommer, Dirk A. Lamprecht, Adrie J. C. Steyn, Kevin Pethe, Jérémie Piton, Karl-Heinz Altmann, Stewart T. Cole
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2018
Materias:	QcrB inhibitor cytochrome bc1 oxidase cytochrome bd oxidase mycobacterial diseases mycobacterial respiration tuberculosis Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/adb9ac67e2c14c6b855d0f2b8719a48c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>

Ejemplares similares